Adding glimepiride to current insulin therapy increases high-molecular weight adiponectin levels to improve glycemic control in poorly controlled type 2 diabetes
Open Access
- 20 March 2014
- journal article
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 6 (1) , 41
Abstract
To observe the efficacy and safety of adding glimepiride to established insulin therapy in poorly controlled type 2 diabetes (T2D) and to assess the relationship of changes in the serum high-molecular weight (HMW) adiponectin levels and glycemic control after glimepiride treatment.Keywords
This publication has 33 references indexed in Scilit:
- Weight changes and their predictors amongst 11 140 patients with type 2 diabetes in the ADVANCE trialDiabetes, Obesity and Metabolism, 2012
- The Risk of Overall Mortality in Patients With Type 2 Diabetes Receiving Glipizide, Glyburide, or Glimepiride MonotherapyDiabetes Care, 2010
- Glycemic Durability of Rosiglitazone, Metformin, or Glyburide MonotherapyNew England Journal of Medicine, 2006
- Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndromeJournal of Clinical Investigation, 2006
- Glimepiride enhances intrinsic peroxisome proliferator-activated receptor-γ activity in 3T3-L1 adipocytesBiochemical and Biophysical Research Communications, 2005
- Comparison of Repaglinide and Nateglinide in Combination With MetforminDiabetes Care, 2003
- Glimepiride and Serum Adiponectin Level in Type 2 Diabetic SubjectsDiabetes Care, 2003
- Impaired Multimerization of Human Adiponectin Mutants Associated with DiabetesJournal of Biological Chemistry, 2003
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Beginning Insulin Treatment of Obese Patients With Evening 70/30 Insulin Plus Glimepiride Versus Insulin AloneDiabetes Care, 1998